Which has better valuation & earnings, SLP or CYRX?

CryoPort has higher revenue and earnings than Simulations Plus. CryoPort is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Simulations Plus $82.06M 4.56 -$64.72M $0.40 46.25 CryoPort $176.18M 4.99 $78.30M -$0.90 N/A

Does the media prefer SLP or CYRX?

In the previous week, Simulations Plus had 7 more articles in the media than CryoPort. MarketBeat recorded 11 mentions for Simulations Plus and 4 mentions for CryoPort. Simulations Plus' average media sentiment score of 0.50 beat CryoPort's score of 0.26 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SLP or DNA?

In the previous week, Ginkgo Bioworks had 9 more articles in the media than Simulations Plus. MarketBeat recorded 20 mentions for Ginkgo Bioworks and 11 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat Ginkgo Bioworks' score of 0.33 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 6 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer SLP or MLAB?

In the previous week, Simulations Plus had 8 more articles in the media than Mesa Laboratories. MarketBeat recorded 11 mentions for Simulations Plus and 3 mentions for Mesa Laboratories. Simulations Plus' average media sentiment score of 0.50 beat Mesa Laboratories' score of 0.22 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Mesa Laboratories 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SLP or CTKB?

In the previous week, Simulations Plus had 7 more articles in the media than Cytek Biosciences. MarketBeat recorded 11 mentions for Simulations Plus and 4 mentions for Cytek Biosciences. Simulations Plus' average media sentiment score of 0.50 beat Cytek Biosciences' score of 0.07 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Simulations Plus (SLP) Competitors

$18.50 0.00 (0.00%)

As of 10/9/2026

Compare

SLP vs. CYRX, DNA, PACB, MLAB, and CTKB

Should you buy Simulations Plus stock or one of its competitors? Simulations Plus's main competitors and comparable companies include CryoPort (CYRX), Ginkgo Bioworks (DNA), Pacific Biosciences of California (PACB), Mesa Laboratories (MLAB), and Cytek Biosciences (CTKB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Simulations Plus compare to CryoPort?

Simulations Plus (NASDAQ:SLP) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

In the previous week, Simulations Plus had 7 more articles in the media than CryoPort. MarketBeat recorded 11 mentions for Simulations Plus and 4 mentions for CryoPort. Simulations Plus' average media sentiment score of 0.50 beat CryoPort's score of 0.26 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Simulations Plus currently has a consensus target price of $17.25, indicating a potential downside of 6.76%. CryoPort has a consensus target price of $18.38, indicating a potential upside of 5.91%. Given CryoPort's stronger consensus rating and higher possible upside, analysts clearly believe CryoPort is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

CryoPort has higher revenue and earnings than Simulations Plus. CryoPort is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.56	-$64.72M	$0.40	46.25
CryoPort	$176.18M	4.99	$78.30M	-$0.90	N/A

Simulations Plus has a net margin of 9.88% compared to CryoPort's net margin of -20.05%. Simulations Plus' return on equity of 13.50% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
CryoPort	-20.05%	-7.20%	-4.30%

Simulations Plus has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 19.1% of Simulations Plus shares are held by insiders. Comparatively, 9.5% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Simulations Plus and CryoPort tied by winning 8 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to Ginkgo Bioworks?

Simulations Plus (NASDAQ:SLP) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Simulations Plus presently has a consensus target price of $17.25, suggesting a potential downside of 6.76%. Ginkgo Bioworks has a consensus target price of $6.33, suggesting a potential downside of 51.09%. Given Simulations Plus' stronger consensus rating and higher probable upside, equities analysts clearly believe Simulations Plus is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Simulations Plus has a net margin of 9.88% compared to Ginkgo Bioworks' net margin of -259.96%. Simulations Plus' return on equity of 13.50% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 19.1% of Simulations Plus shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Simulations Plus has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.56	-$64.72M	$0.40	46.25
Ginkgo Bioworks	$170.15M	5.13	-$312.76M	-$5.01	N/A

In the previous week, Ginkgo Bioworks had 9 more articles in the media than Simulations Plus. MarketBeat recorded 20 mentions for Ginkgo Bioworks and 11 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat Ginkgo Bioworks' score of 0.33 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	6 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Simulations Plus has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Summary

Simulations Plus beats Ginkgo Bioworks on 10 of the 15 factors compared between the two stocks.

How does Simulations Plus compare to Pacific Biosciences of California?

Simulations Plus (NASDAQ:SLP) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

78.1% of Simulations Plus shares are held by institutional investors. 19.1% of Simulations Plus shares are held by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Simulations Plus presently has a consensus target price of $17.25, suggesting a potential downside of 6.76%. Pacific Biosciences of California has a consensus target price of $1.71, suggesting a potential downside of 26.50%. Given Simulations Plus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Simulations Plus is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

Simulations Plus has a net margin of 9.88% compared to Pacific Biosciences of California's net margin of -82.49%. Simulations Plus' return on equity of 13.50% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

Simulations Plus has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.56	-$64.72M	$0.40	46.25
Pacific Biosciences of California	$160.01M	4.53	-$546.38M	-$0.43	N/A

Simulations Plus has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Simulations Plus. MarketBeat recorded 12 mentions for Pacific Biosciences of California and 11 mentions for Simulations Plus. Pacific Biosciences of California's average media sentiment score of 0.51 beat Simulations Plus' score of 0.50 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Simulations Plus beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to Mesa Laboratories?

Simulations Plus (NASDAQ:SLP) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Mesa Laboratories has higher revenue and earnings than Simulations Plus. Simulations Plus is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.56	-$64.72M	$0.40	46.25
Mesa Laboratories	$249.13M	2.87	$6.71M	$0.84	151.80

Simulations Plus has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Simulations Plus has a net margin of 9.88% compared to Mesa Laboratories' net margin of 1.92%. Mesa Laboratories' return on equity of 22.72% beat Simulations Plus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Mesa Laboratories	1.92%	22.72%	9.82%

Simulations Plus presently has a consensus target price of $17.25, indicating a potential downside of 6.76%. Mesa Laboratories has a consensus target price of $110.00, indicating a potential downside of 13.73%. Given Simulations Plus' higher probable upside, research analysts clearly believe Simulations Plus is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Simulations Plus had 8 more articles in the media than Mesa Laboratories. MarketBeat recorded 11 mentions for Simulations Plus and 3 mentions for Mesa Laboratories. Simulations Plus' average media sentiment score of 0.50 beat Mesa Laboratories' score of 0.22 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesa Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are held by institutional investors. 19.1% of Simulations Plus shares are held by insiders. Comparatively, 2.8% of Mesa Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Simulations Plus pays an annual dividend of $0.24 per share and has a dividend yield of 1.3%. Mesa Laboratories pays an annual dividend of $0.64 per share and has a dividend yield of 0.5%. Simulations Plus pays out 60.0% of its earnings in the form of a dividend. Mesa Laboratories pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Simulations Plus is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Simulations Plus beats Mesa Laboratories on 10 of the 17 factors compared between the two stocks.

How does Simulations Plus compare to Cytek Biosciences?

Simulations Plus (NASDAQ:SLP) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Simulations Plus has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Simulations Plus presently has a consensus target price of $17.25, indicating a potential downside of 6.76%. Cytek Biosciences has a consensus target price of $5.56, indicating a potential upside of 2.44%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cytek Biosciences is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Simulations Plus has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.56	-$64.72M	$0.40	46.25
Cytek Biosciences	$201.49M	3.50	-$66.54M	-$0.62	N/A

78.1% of Simulations Plus shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 19.1% of Simulations Plus shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Simulations Plus has a net margin of 9.88% compared to Cytek Biosciences' net margin of -38.98%. Simulations Plus' return on equity of 13.50% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

In the previous week, Simulations Plus had 7 more articles in the media than Cytek Biosciences. MarketBeat recorded 11 mentions for Simulations Plus and 4 mentions for Cytek Biosciences. Simulations Plus' average media sentiment score of 0.50 beat Cytek Biosciences' score of 0.07 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Simulations Plus beats Cytek Biosciences on 12 of the 16 factors compared between the two stocks.

Get Simulations Plus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLP vs. The Competition

Export

Metric	Simulations Plus	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$374.16M	$10.43B	$7.16B	$13.21B
Dividend Yield	N/A	1.45%	2.53%	16.37%
P/E Ratio	46.25	32.42	275.30	26.16
Price / Sales	4.56	106.67	635.97	107.50
Price / Cash	12.93	27.23	76.38	53.09
Price / Book	2.98	6.48	11.22	6.33
Net Income	-$64.72M	$56.67B	$3.50B	$382.15M
7 Day Performance	N/A	-1.01%	-0.89%	-1.40%
1 Month Performance	0.43%	8.89%	-4.42%	-3.47%
1 Year Performance	25.39%	32.14%	7.03%	1.18%

Simulations Plus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLP Simulations Plus	1.1854 of 5 stars	$18.50 flat	$17.25 -6.8%	N/A	$374.16M	$82.06M	46.25	213	Analyst Forecast
CYRX CryoPort	2.6224 of 5 stars	$17.63 -2.8%	$18.38 +4.2%	+74.5%	$894.53M	$176.18M	N/A	738	Analyst Upgrade
DNA Ginkgo Bioworks	1.3946 of 5 stars	$12.32 -17.8%	$6.33 -48.6%	-14.7%	$834.55M	$170.15M	N/A	485	News Coverage Gap Up High Trading Volume
PACB Pacific Biosciences of California	1.329 of 5 stars	$2.69 -6.1%	$1.71 -36.4%	+52.3%	$833.03M	$159.27M	N/A	485	News Coverage Insider Trade Gap Up High Trading Volume
MLAB Mesa Laboratories	1.548 of 5 stars	$138.01 -3.0%	$110.00 -20.3%	+77.9%	$770.92M	$249.13M	163.89	717	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLP) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Simulations Plus (SLP) Competitors

SLP vs. CYRX, DNA, PACB, MLAB, and CTKB

How does Simulations Plus compare to CryoPort?

Summary

How does Simulations Plus compare to Ginkgo Bioworks?

Summary

How does Simulations Plus compare to Pacific Biosciences of California?

Summary

How does Simulations Plus compare to Mesa Laboratories?

Summary

How does Simulations Plus compare to Cytek Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLP vs. The Competition

Simulations Plus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Simulations Plus (SLP) Competitors

SLP vs. CYRX, DNA, PACB, MLAB, and CTKB

How does Simulations Plus compare to CryoPort?

Does the media prefer SLP or CYRX?

Do analysts prefer SLP or CYRX?

Which has better valuation & earnings, SLP or CYRX?

Is SLP or CYRX more profitable?

Which has more risk and volatility, SLP or CYRX?

Do insiders and institutionals have more ownership in SLP or CYRX?

Summary

How does Simulations Plus compare to Ginkgo Bioworks?

Do analysts prefer SLP or DNA?

Is SLP or DNA more profitable?

Do insiders & institutionals hold more shares of SLP or DNA?

Which has preferable earnings and valuation, SLP or DNA?

Does the media prefer SLP or DNA?

Which has more risk & volatility, SLP or DNA?

Summary

How does Simulations Plus compare to Pacific Biosciences of California?

Do insiders and institutionals believe in SLP or PACB?

Do analysts recommend SLP or PACB?

Is SLP or PACB more profitable?

Which has higher earnings and valuation, SLP or PACB?

Which has more volatility and risk, SLP or PACB?

Does the media prefer SLP or PACB?

Summary

How does Simulations Plus compare to Mesa Laboratories?

Which has better earnings & valuation, SLP or MLAB?

Which has more volatility & risk, SLP or MLAB?

Is SLP or MLAB more profitable?

Do analysts prefer SLP or MLAB?

Does the media prefer SLP or MLAB?

Do institutionals and insiders hold more shares of SLP or MLAB?

Is SLP or MLAB a better dividend stock?

Summary

How does Simulations Plus compare to Cytek Biosciences?

Which has more volatility & risk, SLP or CTKB?

Do analysts rate SLP or CTKB?

Which has better valuation and earnings, SLP or CTKB?

Do insiders and institutionals have more ownership in SLP or CTKB?

Is SLP or CTKB more profitable?

Does the media prefer SLP or CTKB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLP vs. The Competition

Simulations Plus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools